UK’s BIA To Argue For Industry In Long-Running Lyrica Patent Dispute
Executive Summary
The UK Supreme Court has agreed to let the BioIndustry Association intervene in a case next month that could impact how much evidence companies need before they can patent their inventions.
You may also be interested in...
UK Patent ‘Plausibility’: Landmark Lyrica Case May Get Supreme Court Ruling By Early Summer
Companies looking forward to a ruling from the Supreme Court on “plausibility” in the UK case involving second medical use patents may have to wait until May or June.
UK Patent ‘Plausibility’: Landmark Lyrica Case May Get Supreme Court Ruling By Early Summer
Companies looking forward to a ruling from the Supreme Court on “plausibility” in the UK case involving second medical use patents may have to wait until May or June.
The Return Of Second Medical Use Patents: Encouraging R&D Or Stifling Innovation?
Industry is eagerly awaiting this month’s judgement of the UK Supreme Court on whether a rule that constitutes a serious obstacle to enforcing patents for important medicines will be removed or modified, say legal experts Charlotte Tillett and Camille Arnold.